A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. Commentary
- Author
- TRACHTENBERG, John; GITTLEMAN, Marc; STEIDLE, Christopher; BARZELL, Winston; FRIEDEL, William; PESSIS, Dennis; FOTHERINGHAM, Nick; CAMPION, Marilyn; GARNICK, Marc B; SHARIFI, Roohollah (Commentator)
1
Affiliated Urologists, Chicago, Illinois, United States
North Indiana Urology, Fort Wayne, Indiana, United States
PRAECIS Pharmaceuticals Inc., Cambridge, Massachusetts, United States
Princess Margaret Hospital, Toronto, Canada
San Diego Urology Center, La Mesa and Amgen Inc., Thousand Oaks, California, United States
South Florida Medical Research, Aventura and Urology Treatment Center, Sarasota, Florida, United States
[1] Urology Clinic, Illinois University Hospitals, Chicago, Illinois, United States
Abarelix Study Group - Source
The Journal of urology. 2002, Vol 167, Num 4, pp 1670-1674 ; ref : 12 ref
- CODEN
- JOURAA
- ISSN
- 0022-5347
- Scientific domain
- Urology, nephrology
- Publisher
- Lippincott Williams & Wilkins, Hagerstown, MD
- Publication country
- United States
- Document type
- Article
- Language
- English
- Keyword (fr)
- Abarélix Agoniste Analogue Antiandrogène Anticancéreux Antihormone Efficacité traitement Essai clinique phase III Etude comparative Etude multicentrique Gonadotrophine RH Homme Leuproréline Prostate Randomisation Traitement associé Tumeur maligne Appareil génital mâle pathologie Appareil urinaire pathologie Facteur libération hormonale Hormone hypothalamique Hormone peptide Prostate pathologie
- Keyword (en)
- Abarelix Agonist Analog Antiandrogen Antineoplastic agent Antihormone Treatment efficiency Phase III trial Comparative study Multicenter study Gonadotropin RH Human Leuprorelin Prostate Randomization Combined treatment Malignant tumor Male genital diseases Urinary system disease Hormone releasing factor Hypothalamic hormone Peptide hormone Prostate disease
- Keyword (es)
- Abarelix Agonista Análogo Antiandrógeno Anticanceroso Antihormona Eficacia tratamiento Ensayo clínico fase III Estudio comparativo Estudio multicéntrico Gonadotropina RH Hombre Leuprorelina Prostata Aleatorización Tratamiento asociado Tumor maligno Aparato genital macho patología Aparato urinario patología Factor liberación hormonal Hormona hipotalámica Hormona péptido Prostata patología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B02 Pharmacology. Drug treatments / 002B02R Antineoplastic agents / 002B02R02 Chemotherapy
- Discipline
- Pharmacological treatments
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 13575687
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1097/00005392-200204000-00021 
https://dx.doi.org/10.1097/00005392-200204000-00021
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1097\/00005392-200204000-00021\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:146:\"A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. Commentary\";s:9:\"\u0000*\u0000jtitle\";s:22:\"The Journal of urology\";s:9:\"\u0000*\u0000stitle\";s:7:\"J. urol\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:3:\"167\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:4:\"1670\";s:8:\"\u0000*\u0000epage\";s:4:\"1674\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-5347\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:12:\"TRACHTENBERG\";s:10:\"\u0000*\u0000aufirst\";s:4:\"John\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:15:\"GITTLEMAN, Marc\";i:1;s:20:\"STEIDLE, Christopher\";i:2;s:16:\"BARZELL, Winston\";i:3;s:16:\"FRIEDEL, William\";i:4;s:14:\"PESSIS, Dennis\";i:5;s:18:\"FOTHERINGHAM, Nick\";i:6;s:16:\"CAMPION, Marilyn\";i:7;s:15:\"GARNICK, Marc B\";i:8;s:18:\"SHARIFI, Roohollah\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JOURAA\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:146:\"A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. Commentary\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1097\/00005392-200204000-00021\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:146:\"A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. Commentary\";s:9:\"\u0000*\u0000jtitle\";s:22:\"The Journal of urology\";s:9:\"\u0000*\u0000stitle\";s:7:\"J. urol\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:3:\"167\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:4:\"1670\";s:8:\"\u0000*\u0000epage\";s:4:\"1674\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-5347\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:12:\"TRACHTENBERG\";s:10:\"\u0000*\u0000aufirst\";s:4:\"John\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:15:\"GITTLEMAN, Marc\";i:1;s:20:\"STEIDLE, Christopher\";i:2;s:16:\"BARZELL, Winston\";i:3;s:16:\"FRIEDEL, William\";i:4;s:14:\"PESSIS, Dennis\";i:5;s:18:\"FOTHERINGHAM, Nick\";i:6;s:16:\"CAMPION, Marilyn\";i:7;s:15:\"GARNICK, Marc B\";i:8;s:18:\"SHARIFI, Roohollah\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JOURAA\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:146:\"A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. Commentary\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:32:\"10.1097\/00005392-200204000-00021\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1097\/00005392-200204000-00021\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:146:\"A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. Commentary\";s:9:\"\u0000*\u0000jtitle\";s:22:\"The Journal of urology\";s:9:\"\u0000*\u0000stitle\";s:7:\"J. urol\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:3:\"167\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:4:\"1670\";s:8:\"\u0000*\u0000epage\";s:4:\"1674\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-5347\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:12:\"TRACHTENBERG\";s:10:\"\u0000*\u0000aufirst\";s:4:\"John\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:15:\"GITTLEMAN, Marc\";i:1;s:20:\"STEIDLE, Christopher\";i:2;s:16:\"BARZELL, Winston\";i:3;s:16:\"FRIEDEL, William\";i:4;s:14:\"PESSIS, Dennis\";i:5;s:18:\"FOTHERINGHAM, Nick\";i:6;s:16:\"CAMPION, Marilyn\";i:7;s:15:\"GARNICK, Marc B\";i:8;s:18:\"SHARIFI, Roohollah\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JOURAA\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:146:\"A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. Commentary\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1097\/00005392-200204000-00021\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:146:\"A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. Commentary\";s:9:\"\u0000*\u0000jtitle\";s:22:\"The Journal of urology\";s:9:\"\u0000*\u0000stitle\";s:7:\"J. urol\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:3:\"167\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:4:\"1670\";s:8:\"\u0000*\u0000epage\";s:4:\"1674\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-5347\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:12:\"TRACHTENBERG\";s:10:\"\u0000*\u0000aufirst\";s:4:\"John\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:15:\"GITTLEMAN, Marc\";i:1;s:20:\"STEIDLE, Christopher\";i:2;s:16:\"BARZELL, Winston\";i:3;s:16:\"FRIEDEL, William\";i:4;s:14:\"PESSIS, Dennis\";i:5;s:18:\"FOTHERINGHAM, Nick\";i:6;s:16:\"CAMPION, Marilyn\";i:7;s:15:\"GARNICK, Marc B\";i:8;s:18:\"SHARIFI, Roohollah\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JOURAA\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:146:\"A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. Commentary\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:32:\"10.1097\/00005392-200204000-00021\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:146:\"A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. Commentary\";s:9:\"\u0000*\u0000jtitle\";s:22:\"The Journal of urology\";s:9:\"\u0000*\u0000stitle\";s:7:\"J. urol\";s:7:\"\u0000*\u0000date\";s:4:\"2002\";s:9:\"\u0000*\u0000volume\";s:3:\"167\";s:8:\"\u0000*\u0000issue\";s:1:\"4\";s:8:\"\u0000*\u0000spage\";s:4:\"1670\";s:8:\"\u0000*\u0000epage\";s:4:\"1674\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0022-5347\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:12:\"TRACHTENBERG\";s:10:\"\u0000*\u0000aufirst\";s:4:\"John\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:9:{i:0;s:15:\"GITTLEMAN, Marc\";i:1;s:20:\"STEIDLE, Christopher\";i:2;s:16:\"BARZELL, Winston\";i:3;s:16:\"FRIEDEL, William\";i:4;s:14:\"PESSIS, Dennis\";i:5;s:18:\"FOTHERINGHAM, Nick\";i:6;s:16:\"CAMPION, Marilyn\";i:7;s:15:\"GARNICK, Marc B\";i:8;s:18:\"SHARIFI, Roohollah\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"JOURAA\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:146:\"A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. Commentary\";s:8:\"\u0000*\u0000place\";s:14:\"Hagerstown, MD\";s:6:\"\u0000*\u0000pub\";s:29:\"Lippincott Williams & Wilkins\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:0:\"\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
